FDA approves Mylan genital herpes ointment
PITTSBURGH — The Food and Drug Administration has approved a new drug for genital herpes made by Mylan, the drug maker said Wednesday.
Mylan announced the approval of acyclovir ointment in the 5% strength. The drug is a generic version of Valeant International’s Zovirax, used to manage initial genital herpes and in limited, non-life-threatening mucocutaneous herpes simplex virus infections in patients with compromised immune systems.
Various versions of the drug had sales of about $230 million in 2012, according to IMS Health. Mylan said it would start shipping the drug immediately.
NCPA responds to CMS call letter
ALEXANDRIA, Va. — The recent call letter released by the Centers for Medicare and Medicaid Services addresses issues that can have an adverse effect on the program’s cost and quality of care, a trade group representing independent retail pharmacies said Wednesday.
Commenting on the CMS’ announcement, the National Community Pharmacists Association said it had prepared a detailed list for its members.
"NCPA staff and members will continue to work constructively with Medicare, Congress and others to maximize the health outcomes and cost efficiency of the Medicare prescription drug program," NCPA president and CEO B. Douglas Hoey said. "NCPA thanks its community pharmacist members and their patients who have weighed in with Medicare officials regarding these issues in the weeks and months leading up to the final 2014 call letter."
In particular, the NCPA said "egregious" pharmacy audits were collecting substantial amounts of money from pharmacies over "trivial clerical issues" instead of targeting a few bad actors; the group expressed agreement with Medicare’s statement that Part D plans should only recoup the full amount of a prescription claim under certain circumstances, such as a fraudulent or duplicate claim. Secondly, the group expressed support for Medicare’s statement that the best way to encourage price competition and lower costs is to allow any willing pharmacy to participate in preferred networks because preferred-pharmacy drug plans were creating concerns about access for elderly people, particularly those in rural areas, by excluding many independent pharmacies and regional chains. Thirdly, the NCPA said auto-shipping by mail-order pharmacies generated wasteful spending and inconvenience for patients, noting Medicare’s statement that pharmacies offering drug-disposal programs have documented patients turning in large quantities of unneeded medication received from auto-ship refill programs and that stronger opt-in protections may deter waste. In addition, the NCPA said, recent research has indicated that community pharmacies provide 90-day medication supplies at lower costs than mail-order pharmacies and substitute cheaper generics more often.
Patients who adhere to generic statins have lower overall health costs compared with patients adherent to branded statins
SAN DIEGO — Improving adherence to generic statin drugs for high cholesterol can reduce the costs of health care in a way that adherence to branded statins historically couldn’t, according to a new study.
The study, conducted by pharmacy benefit manager Prime Therapeutics and Blue Cross and Blue Shield of Minnesota, is being presented Wednesday at the Academy of Managed Care Pharmacy’s 25th annual meeting and expo in San Diego. The study found that adherence to generic statin therapy resulted in lower hospitalization rates, which offset higher pharmacy costs and resulted in lower total costs of care. Previous research focusing on adherence to branded statin drugs showed adherence was associated with fewer medical problems but higher total costs, due in part to the higher costs of the drugs.
"We know adherence to statin therapy can keep patients out of the hospital, but in the past, this also came with a higher cost of care," Prime Therapeutics director of health outcomes Patrick Gleason said. "As more generic statins enter the market, we see that generic statins can not only help prevent hospitalizations, but can also improve the quality of life through fewer hospitalizations and contribute to lower overall healthcare costs."
The study was based on pharmacy and medical claims data from 1.2 million members continuously enrolled from 2007 through 2010 and included nearly 22,000 members, of whom 46% were adherent and 54% weren’t. Among the adherent patients, researchers saw a hospitalization rate of 25%, compared with 27.6% of those who were not adherent, as well as medical costs of $11,353, compared with $12,375 among the nonadherent patients. Pharmacy costs for the adherent patients were still higher than for the nonadherent patients — $4,016 and $3,079, respectively — but the total cost of care was lower: $15,290 for adherent patients and $15,451 for nonadherent patients.